In the future, if it is possible to measure the serum circulating mRNA of CCNB2 easily, this may be useful for selecting cases to be screened for TP53 variants in ACC, determining therapeutic effects, and predicting recurrence. The gene discussed is CCNB2; the disease is adrenal cortex carcinoma.